サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：エビの疾病診断の世界市場 - 世界の業界分析、規模、シェア、成長、動向、予測（2031年）- 製品別、技術別、グレード別、用途別、エンドユーザー別、地域別
市場調査レポート
商品コード
1394147

エビの疾病診断の世界市場 - 世界の業界分析、規模、シェア、成長、動向、予測（2031年）- 製品別、技術別、グレード別、用途別、エンドユーザー別、地域別

Shrimp Disease Diagnostics Market - Global Industry Analysis, Size, Share, Growth, Trends, & Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America & Middle East & Africa)

出版日
ページ情報
英文 215 Pages
納期
2～5営業日
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.64円
エビの疾病診断の世界市場 - 世界の業界分析、規模、シェア、成長、動向、予測（2031年）- 製品別、技術別、グレード別、用途別、エンドユーザー別、地域別
出版日: 2023年12月06日
発行: Fairfield Market Research
ページ情報: 英文 215 Pages
納期: 2～5営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

世界のエビの疾病診断の市場規模は、2024年に約4億8,400万米ドルの収益に達し、2031年末には約8億米ドルになると予測されるなど、著しい成長を遂げようとしています。この盛況な分野は、エビの世界の需要の急増に後押しされた動物診断産業の重要な構成要素です。

世界の水産物消費の主食であるエビの需要の高まりが、エビの疾病診断市場の拡大の促進要因となっています。エビの養殖は人間の食料と栄養供給に不可欠であり、この需要は海産と淡水の両方のエビ生産によってもたらされています。エビ病害診断薬は、エビ個体群の健康を維持し、感染症の蔓延を防ぎ、エビ養殖の持続可能性を守る上で極めて重要な役割を果たしています。

特に白点症候群（WSS）のような、現在治療法が限られている脅威については、早期発見が重要視されています。PCRやDNAハイブリダイゼーションのような高度な診断ツールは、エビ養殖におけるバイオセキュリティを強化し、最善の管理方法を推進する上で役立っています。

有望な成長軌道にもかかわらず、エビの疾病診断市場はいくつかの課題に直面しています。検査室での集中的な病害検出はコストと時間がかかり、専門施設と熟練した人材を必要とします。エビの疾病診断に関する規制の枠組みがまだ発展途上の地域もあり、市場の成長を阻害する可能性があります。

さらに、アジアのような発展途上国では、検疫、サーベイランス、病害識別の能力強化が必要であり、生きた動物の輸入に伴う病害伝播リスクを軽減するために不可欠です。一部の地域ではすでに、国内の甲殻類の個体群を保護し、持続可能な慣行を確保するための管理規制を実施しています。

当レポートでは、世界のアイデンティティおよびアクセス管理市場について調査し、市場の概要とともに、コンポーネント別、展開別、ソリューション別、業界別、地域別動向、および市場に参入する企業の競合動向などを提供しています。

目次

第1章 エグゼクティブサマリー

第2章 市場概要

  • 市場の定義とセグメンテーション
  • 市場力学
  • バリューチェーン分析
  • ポーターのファイブフォース分析
  • COVID-19の影響分析
  • ウクライナとロシアの紛争の影響
  • 経済概要
  • PESTLE分析

第3章 世界のエビ疾患診断市場の見通し、2018年～2031年

  • 世界のエビ病診断市場の見通し、試薬別、金額、2018年～2031年
  • 世界のエビの病気診断市場の見通し、疾患別、金額、2018年～2031年
  • 世界のエビ疾患診断市場の見通し、エンドユーザー別、金額、2018年～2031年
  • 世界のエビの病気診断市場の見通し、地域別、金額、2018年～2031年

第4章 北米のエビの病気診断市場の見通し、2018年～2031年

第5章 欧州のエビ疾患診断市場の見通し、2018年～2031年

第6章 アジア太平洋のエビ疾患診断市場の見通し、2018年～2031年

第7章 ラテンアメリカのエビの病気診断市場の見通し、2018年～2031年

第8章 中東・アフリカのエビ疾患診断市場の見通し、2018年～2031年

第9章 競合情勢

  • 疾患対試薬のヒートマップ
  • 企業の市場シェア分析、2023年
  • 競争力ダッシュボード
  • 企業プロファイル
    • HiMedia Laboratories
    • Speedy Assay Sdn Bhd
    • REAGEN LLC
    • FUJIKURA KASEI CO., LTD.
    • GeneReach Biotechnology Corp.
    • Thermo Fisher Scientific
    • Lab - Ind Resource Sdn Bhd.
    • SUREBIO
    • Auro Biotechnologies Pvt. Ltd.

第10章 付録

目次

The global Shrimp Disease Diagnostics Market is poised for remarkable growth, with revenues reaching approximately US$ 484.0 Million in 2024 and a projected valuation of about US$ 800.0 Million by the end of 2031, according to recent report by Fairfield Market Research. This thriving sector is a vital component of the animal diagnostics industry, propelled by the surging global demand for shrimp.

Biosecurity for Healthy Shrimps and Disease Prevention

The escalating demand for shrimp, a staple in global seafood consumption, has been a driving force behind the expansion of the shrimp disease diagnostics market. Shrimp aquaculture is crucial for human food and nutrition supply, and this demand is driven by both marine and freshwater shrimp production. Shrimp disease diagnostics play a pivotal role in maintaining the health of shrimp populations, preventing the spread of infectious diseases, and safeguarding the sustainability of shrimp farming.

In particular, the market has witnessed an increased focus on early disease detection, especially for threats like White Spot Syndrome (WSS), where therapeutic options are currently limited. Advanced diagnostic tools, such as PCR and DNA hybridization, have been instrumental in enhancing biosecurity and promoting best management practices in shrimp farming.

Challenges and Opportunities

Despite its promising growth trajectory, the shrimp disease diagnostics market faces several challenges. The centralized nature of disease detection in laboratories can be costly and time-consuming, demanding specialized facilities and skilled personnel. Regulatory frameworks for shrimp disease diagnostics are still evolving in some regions, potentially impeding market growth.

In addition, the need for enhanced capacity in developing nations, such as those in Asia, to carry out quarantine, surveillance, and disease identification is critical to mitigate disease transmission risks associated with live animal importation. Some regions have already implemented management regulations to protect domestic crustacean populations and ensure sustainable practices.

Country-wise Insights

United States: The U.S. market is set to expand the global market due to its access to advanced molecular diagnostic tools. Factors such as a higher prevalence of infections, rising healthcare expenditure, efficient healthcare infrastructures, and skilled laboratory technicians are contributing to market growth. Collaborations within the aquaculture industry are furthering the focus on health management and disease prevention.

China: As the world's largest consumer of seafood, China is a dominant player in shrimp farming and disease diagnostics. Government regulations ensure seafood safety and quality, prompting an increased demand for disease diagnostics to comply with these standards. Innovations like real-time PCR and ELISA assays have enhanced diagnosis accuracy and speed, further driving adoption.

Germany: Germany's significant seafood market and rising shrimp demand have led to a greater need for effective disease diagnostics. The presence of key market players in the shrimp disease diagnostics market has increased product availability and competition. The incidence of shrimp diseases in the region, including WSSV, YHV, and TSV, has also surged.

Competitive Landscape

Key players in the shrimp disease diagnostics market are actively collaborating with ISO-accredited government laboratories and universities to develop and commercialize innovative diagnostic products. These collaborations aim to leverage advanced technologies for manufacturing genetic diagnostics tools.

Notable companies in the market include:

  • HiMedia Laboratories
  • Speedy Assay Sdn Bhd
  • REAGEN LLC
  • FUJIKURA KASEI CO., LTD.
  • GeneReach Biotechnology Corp.
  • Thermo Fisher Scientific
  • Lab - Ind Resource Sdn Bhd.
  • SUREBIO
  • Auro Biotechnologies Pvt. Ltd.

Key Segments Covered in Shrimp disease diagnostics Industry Research

Reagent:

  • Rapid Testing Kits
  • Assay Based Kits

Disease:

  • WSSV (White Spot Syndrome Virus)
  • TSV (Taura Syndrome Virus)
  • YHV/GAV (Yellow Head/Gill Associated Virus)
  • IHHNV (Infectious Hypodermal and Hematopoietic Virus)
  • HPV (Hepatopancreatic Parvovirus)
  • MBV (Monodon Baculovirus)
  • IMNV (Infectious Myonecrosis Virus)
  • NHP-B (Necrotising Hepatopancreatitis Bacteria)
  • MoV (Mourilyan Virus)
  • Early Mortality Syndrome (EMS)

End User:

  • Fisheries
  • Aquaculture Laboratories
  • Marine Laboratories
  • Education and Research Institutes
  • Others

Region:

  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • Middle East and Africa (MEA)

Table of Contents

1. Executive Summary

  • 1.1. Global Shrimp Disease Diagnostics Market Snapshot
  • 1.2. Future Projections
  • 1.3. Key Market Trends
  • 1.4. Regional Snapshot, by Value, 2023
  • 1.5. Analyst Recommendations

2. Market Overview

  • 2.1. Market Definitions and Segmentations
  • 2.2. Market Dynamics
    • 2.2.1. Drivers
    • 2.2.2. Restraints
    • 2.2.3. Market Opportunities
  • 2.3. Value Chain Analysis
  • 2.4. Porter's Five Forces Analysis
  • 2.5. COVID-19 Impact Analysis
    • 2.5.1. Supply
    • 2.5.2. Demand
  • 2.6. Impact of Ukraine-Russia Conflict
  • 2.7. Economic Overview
    • 2.7.1. World Economic Projections
  • 2.8. PESTLE Analysis

3. Global Shrimp Disease Diagnostics Market Outlook, 2018 - 2031

  • 3.1. Global Shrimp Disease Diagnostics Market Outlook, by Reagent, Value (US$ Bn), 2018 - 2031
    • 3.1.1. Key Highlights
      • 3.1.1.1. Rapid Testing Kits
      • 3.1.1.2. Assay Based Kits
  • 3.2. Global Shrimp Disease Diagnostics Market Outlook, by Disease, Value (US$ Bn), 2018 - 2031
    • 3.2.1. Key Highlights
      • 3.2.1.1. WSSV (White Spot Syndrome Virus)
      • 3.2.1.2. TSV (Taura Syndrome Virus)
      • 3.2.1.3. YHV/GAV (Yellow Head/Gill Associated Virus)
      • 3.2.1.4. IHHNV (Infectious Hypodermal and Hematopoietic Virus)
      • 3.2.1.5. HPV (Hepatopancreatic Parvovirus)
      • 3.2.1.6. MBV (Monodon Baculovirus)
      • 3.2.1.7. IMNV (Infectious Myonecrosis Virus)
      • 3.2.1.8. NHP-B (Necrotising Hepatopancreatitis Bacteria)
      • 3.2.1.9. MoV (Mourilyan Virus)
      • 3.2.1.10. Early Mortality Syndrome (EMS)
  • 3.3. Global Shrimp Disease Diagnostics Market Outlook, by End User, Value (US$ Bn), 2018 - 2031
    • 3.3.1. Key Highlights
      • 3.3.1.1. Fisheries
      • 3.3.1.2. Aquaculture Laboratories
      • 3.3.1.3. Marine Laboratories
      • 3.3.1.4. Education and Research Institutes
      • 3.3.1.5. Others
  • 3.4. Global Shrimp Disease Diagnostics Market Outlook, by Region, Value (US$ Bn), 2018 - 2031
    • 3.4.1. Key Highlights
      • 3.4.1.1. North America
      • 3.4.1.2. Europe
      • 3.4.1.3. Asia Pacific
      • 3.4.1.4. Latin America
      • 3.4.1.5. Middle East & Africa

4. North America Shrimp Disease Diagnostics Market Outlook, 2018 - 2031

  • 4.1. North America Shrimp Disease Diagnostics Market Outlook, by Reagent, Value (US$ Bn), 2018 - 2031
    • 4.1.1. Key Highlights
      • 4.1.1.1. Rapid Testing Kits
      • 4.1.1.2. Assay Based Kits
  • 4.2. North America Shrimp Disease Diagnostics Market Outlook, by Disease, Value (US$ Bn), 2018 - 2031
    • 4.2.1. Key Highlights
      • 4.2.1.1. WSSV (White Spot Syndrome Virus)
      • 4.2.1.2. TSV (Taura Syndrome Virus)
      • 4.2.1.3. YHV/GAV (Yellow Head/Gill Associated Virus)
      • 4.2.1.4. IHHNV (Infectious Hypodermal and Hematopoietic Virus)
      • 4.2.1.5. HPV (Hepatopancreatic Parvovirus)
      • 4.2.1.6. MBV (Monodon Baculovirus)
      • 4.2.1.7. IMNV (Infectious Myonecrosis Virus)
      • 4.2.1.8. NHP-B (Necrotising Hepatopancreatitis Bacteria)
      • 4.2.1.9. MoV (Mourilyan Virus)
      • 4.2.1.10. Early Mortality Syndrome (EMS)
  • 4.3. North America Shrimp Disease Diagnostics Market Outlook, by End User, Value (US$ Bn), 2018 - 2031
    • 4.3.1. Key Highlights
      • 4.3.1.1. Fisheries
      • 4.3.1.2. Aquaculture Laboratories
      • 4.3.1.3. Marine Laboratories
      • 4.3.1.4. Education and Research Institutes
      • 4.3.1.5. Others
  • 4.4. North America Shrimp Disease Diagnostics Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
    • 4.4.1. Key Highlights
      • 4.4.1.1. U.S. Shrimp Disease Diagnostics Market by Reagent, Value (US$ Bn), 2018 - 2031
      • 4.4.1.2. U.S. Shrimp Disease Diagnostics Market by Disease, Value (US$ Bn), 2018 - 2031
      • 4.4.1.3. U.S. Shrimp Disease Diagnostics Market by End User, Value (US$ Bn), 2018 - 2031
      • 4.4.1.4. Canada Shrimp Disease Diagnostics Market by Reagent, Value (US$ Bn), 2018 - 2031
      • 4.4.1.5. Canada Shrimp Disease Diagnostics Market by Disease, Value (US$ Bn), 2018 - 2031
      • 4.4.1.6. Canada Shrimp Disease Diagnostics Market by End User, Value (US$ Bn), 2018 - 2031
    • 4.4.2. BPS Analysis/Market Attractiveness Analysis

5. Europe Shrimp Disease Diagnostics Market Outlook, 2018 - 2031

  • 5.1. Europe Shrimp Disease Diagnostics Market Outlook, by Reagent, Value (US$ Bn), 2018 - 2031
    • 5.1.1. Key Highlights
      • 5.1.1.1. Rapid Testing Kits
      • 5.1.1.2. Assay Based Kits
  • 5.2. Europe Shrimp Disease Diagnostics Market Outlook, by Disease, Value (US$ Bn), 2018 - 2031
    • 5.2.1. Key Highlights
      • 5.2.1.1. WSSV (White Spot Syndrome Virus)
      • 5.2.1.2. TSV (Taura Syndrome Virus)
      • 5.2.1.3. YHV/GAV (Yellow Head/Gill Associated Virus)
      • 5.2.1.4. IHHNV (Infectious Hypodermal and Hematopoietic Virus)
      • 5.2.1.5. HPV (Hepatopancreatic Parvovirus)
      • 5.2.1.6. MBV (Monodon Baculovirus)
      • 5.2.1.7. IMNV (Infectious Myonecrosis Virus)
      • 5.2.1.8. NHP-B (Necrotising Hepatopancreatitis Bacteria)
      • 5.2.1.9. MoV (Mourilyan Virus)
      • 5.2.1.10. Early Mortality Syndrome (EMS)
  • 5.3. Europe Shrimp Disease Diagnostics Market Outlook, by End User, Value (US$ Bn), 2018 - 2031
    • 5.3.1. Key Highlights
      • 5.3.1.1. Fisheries
      • 5.3.1.2. Aquaculture Laboratories
      • 5.3.1.3. Marine Laboratories
      • 5.3.1.4. Education and Research Institutes
      • 5.3.1.5. Others
  • 5.4. Europe Shrimp Disease Diagnostics Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
    • 5.4.1. Key Highlights
      • 5.4.1.1. Germany Shrimp Disease Diagnostics Market by Reagent, Value (US$ Bn), 2018 - 2031
      • 5.4.1.2. Germany Shrimp Disease Diagnostics Market by Disease, Value (US$ Bn), 2018 - 2031
      • 5.4.1.3. Germany Shrimp Disease Diagnostics Market by End User, Value (US$ Bn), 2018 - 2031
      • 5.4.1.4. U.K. Shrimp Disease Diagnostics Market by Reagent, Value (US$ Bn), 2018 - 2031
      • 5.4.1.5. U.K. Shrimp Disease Diagnostics Market by Disease, Value (US$ Bn), 2018 - 2031
      • 5.4.1.6. U.K. Shrimp Disease Diagnostics Market by End User, Value (US$ Bn), 2018 - 2031
      • 5.4.1.7. France Shrimp Disease Diagnostics Market by Reagent, Value (US$ Bn), 2018 - 2031
      • 5.4.1.8. France Shrimp Disease Diagnostics Market by Disease, Value (US$ Bn), 2018 - 2031
      • 5.4.1.9. France Shrimp Disease Diagnostics Market by End User, Value (US$ Bn), 2018 - 2031
      • 5.4.1.10. Italy Shrimp Disease Diagnostics Market by Reagent, Value (US$ Bn), 2018 - 2031
      • 5.4.1.11. Italy Shrimp Disease Diagnostics Market by Disease, Value (US$ Bn), 2018 - 2031
      • 5.4.1.12. Italy Shrimp Disease Diagnostics Market by End User, Value (US$ Bn), 2018 - 2031
      • 5.4.1.13. Turkey Shrimp Disease Diagnostics Market by Reagent, Value (US$ Bn), 2018 - 2031
      • 5.4.1.14. Turkey Shrimp Disease Diagnostics Market by Disease, Value (US$ Bn), 2018 - 2031
      • 5.4.1.15. Turkey Shrimp Disease Diagnostics Market by End User, Value (US$ Bn), 2018 - 2031
      • 5.4.1.16. Russia Shrimp Disease Diagnostics Market by Reagent, Value (US$ Bn), 2018 - 2031
      • 5.4.1.17. Russia Shrimp Disease Diagnostics Market by Disease, Value (US$ Bn), 2018 - 2031
      • 5.4.1.18. Russia Shrimp Disease Diagnostics Market by End User, Value (US$ Bn), 2018 - 2031
      • 5.4.1.19. Rest of Europe Shrimp Disease Diagnostics Market by Reagent, Value (US$ Bn), 2018 - 2031
      • 5.4.1.20. Rest of Europe Shrimp Disease Diagnostics Market by Disease, Value (US$ Bn), 2018 - 2031
      • 5.4.1.21. Rest of Europe Shrimp Disease Diagnostics Market by End User, Value (US$ Bn), 2018 - 2031
    • 5.4.2. BPS Analysis/Market Attractiveness Analysis

6. Asia Pacific Shrimp Disease Diagnostics Market Outlook, 2018 - 2031

  • 6.1. Asia Pacific Shrimp Disease Diagnostics Market Outlook, by Reagent, Value (US$ Bn), 2018 - 2031
    • 6.1.1. Key Highlights
      • 6.1.1.1. Rapid Testing Kits
      • 6.1.1.2. Assay Based Kits
  • 6.2. Asia Pacific Shrimp Disease Diagnostics Market Outlook, by Disease, Value (US$ Bn), 2018 - 2031
    • 6.2.1. Key Highlights
      • 6.2.1.1. WSSV (White Spot Syndrome Virus)
      • 6.2.1.2. TSV (Taura Syndrome Virus)
      • 6.2.1.3. YHV/GAV (Yellow Head/Gill Associated Virus)
      • 6.2.1.4. IHHNV (Infectious Hypodermal and Hematopoietic Virus)
      • 6.2.1.5. HPV (Hepatopancreatic Parvovirus)
      • 6.2.1.6. MBV (Monodon Baculovirus)
      • 6.2.1.7. IMNV (Infectious Myonecrosis Virus)
      • 6.2.1.8. NHP-B (Necrotising Hepatopancreatitis Bacteria)
      • 6.2.1.9. MoV (Mourilyan Virus)
      • 6.2.1.10. Early Mortality Syndrome (EMS)
  • 6.3. Asia Pacific Shrimp Disease Diagnostics Market Outlook, by End User, Value (US$ Bn), 2018 - 2031
    • 6.3.1. Key Highlights
      • 6.3.1.1. Fisheries
      • 6.3.1.2. Aquaculture Laboratories
      • 6.3.1.3. Marine Laboratories
      • 6.3.1.4. Education and Research Institutes
      • 6.3.1.5. Others
  • 6.4. Asia Pacific Shrimp Disease Diagnostics Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
    • 6.4.1. Key Highlights
      • 6.4.1.1. China Shrimp Disease Diagnostics Market by Reagent, Value (US$ Bn), 2018 - 2031
      • 6.4.1.2. China Shrimp Disease Diagnostics Market by Disease, Value (US$ Bn), 2018 - 2031
      • 6.4.1.3. China Shrimp Disease Diagnostics Market by End User, Value (US$ Bn), 2018 - 2031
      • 6.4.1.4. Japan Shrimp Disease Diagnostics Market by Reagent, Value (US$ Bn), 2018 - 2031
      • 6.4.1.5. Japan Shrimp Disease Diagnostics Market by Disease, Value (US$ Bn), 2018 - 2031
      • 6.4.1.6. Japan Shrimp Disease Diagnostics Market by End User, Value (US$ Bn), 2018 - 2031
      • 6.4.1.7. South Korea Shrimp Disease Diagnostics Market by Reagent, Value (US$ Bn), 2018 - 2031
      • 6.4.1.8. South Korea Shrimp Disease Diagnostics Market by Disease, Value (US$ Bn), 2018 - 2031
      • 6.4.1.9. South Korea Shrimp Disease Diagnostics Market by End User, Value (US$ Bn), 2018 - 2031
      • 6.4.1.10. India Shrimp Disease Diagnostics Market by Reagent, Value (US$ Bn), 2018 - 2031
      • 6.4.1.11. India Shrimp Disease Diagnostics Market by Disease, Value (US$ Bn), 2018 - 2031
      • 6.4.1.12. India Shrimp Disease Diagnostics Market by End User, Value (US$ Bn), 2018 - 2031
      • 6.4.1.13. Southeast Asia Shrimp Disease Diagnostics Market by Reagent, Value (US$ Bn), 2018 - 2031
      • 6.4.1.14. Southeast Asia Shrimp Disease Diagnostics Market by Disease, Value (US$ Bn), 2018 - 2031
      • 6.4.1.15. Southeast Asia Shrimp Disease Diagnostics Market by End User, Value (US$ Bn), 2018 - 2031
      • 6.4.1.16. Rest of Asia Pacific Shrimp Disease Diagnostics Market by Reagent, Value (US$ Bn), 2018 - 2031
      • 6.4.1.17. Rest of Asia Pacific Shrimp Disease Diagnostics Market by Disease, Value (US$ Bn), 2018 - 2031
      • 6.4.1.18. Rest of Asia Pacific Shrimp Disease Diagnostics Market by End User, Value (US$ Bn), 2018 - 2031
    • 6.4.2. BPS Analysis/Market Attractiveness Analysis

7. Latin America Shrimp Disease Diagnostics Market Outlook, 2018 - 2031

  • 7.1. Latin America Shrimp Disease Diagnostics Market Outlook, by Reagent, Value (US$ Bn), 2018 - 2031
    • 7.1.1. Key Highlights
      • 7.1.1.1. Rapid Testing Kits
      • 7.1.1.2. Assay Based Kits
  • 7.2. Latin America Shrimp Disease Diagnostics Market Outlook, by Disease, Value (US$ Bn), 2018 - 2031
      • 7.2.1.1. WSSV (White Spot Syndrome Virus)
      • 7.2.1.2. TSV (Taura Syndrome Virus)
      • 7.2.1.3. YHV/GAV (Yellow Head/Gill Associated Virus)
      • 7.2.1.4. IHHNV (Infectious Hypodermal and Hematopoietic Virus)
      • 7.2.1.5. HPV (Hepatopancreatic Parvovirus)
      • 7.2.1.6. MBV (Monodon Baculovirus)
      • 7.2.1.7. IMNV (Infectious Myonecrosis Virus)
      • 7.2.1.8. NHP-B (Necrotising Hepatopancreatitis Bacteria)
      • 7.2.1.9. MoV (Mourilyan Virus)
      • 7.2.1.10. Early Mortality Syndrome (EMS)
  • 7.3. Latin America Shrimp Disease Diagnostics Market Outlook, by End User, Value (US$ Bn), 2018 - 2031
    • 7.3.1. Key Highlights
      • 7.3.1.1. Fisheries
      • 7.3.1.2. Aquaculture Laboratories
      • 7.3.1.3. Marine Laboratories
      • 7.3.1.4. Education and Research Institutes
      • 7.3.1.5. Others
  • 7.4. Latin America Shrimp Disease Diagnostics Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
    • 7.4.1. Key Highlights
      • 7.4.1.1. Brazil Shrimp Disease Diagnostics Market by Reagent, Value (US$ Bn), 2018 - 2031
      • 7.4.1.2. Brazil Shrimp Disease Diagnostics Market by Disease, Value (US$ Bn), 2018 - 2031
      • 7.4.1.3. Brazil Shrimp Disease Diagnostics Market by End User, Value (US$ Bn), 2018 - 2031
      • 7.4.1.4. Mexico Shrimp Disease Diagnostics Market by Reagent, Value (US$ Bn), 2018 - 2031
      • 7.4.1.5. Mexico Shrimp Disease Diagnostics Market by Disease, Value (US$ Bn), 2018 - 2031
      • 7.4.1.6. Mexico Shrimp Disease Diagnostics Market by End User, Value (US$ Bn), 2018 - 2031
      • 7.4.1.7. Argentina Shrimp Disease Diagnostics Market by Reagent, Value (US$ Bn), 2018 - 2031
      • 7.4.1.8. Argentina Shrimp Disease Diagnostics Market by Disease, Value (US$ Bn), 2018 - 2031
      • 7.4.1.9. Argentina Shrimp Disease Diagnostics Market by End User, Value (US$ Bn), 2018 - 2031
      • 7.4.1.10. Rest of Latin America Shrimp Disease Diagnostics Market by Reagent, Value (US$ Bn), 2018 - 2031
      • 7.4.1.11. Rest of Latin America Shrimp Disease Diagnostics Market by Disease, Value (US$ Bn), 2018 - 2031
      • 7.4.1.12. Rest of Latin America Shrimp Disease Diagnostics Market by End User, Value (US$ Bn), 2018 - 2031
    • 7.4.2. BPS Analysis/Market Attractiveness Analysis

8. Middle East & Africa Shrimp Disease Diagnostics Market Outlook, 2018 - 2031

  • 8.1. Middle East & Africa Shrimp Disease Diagnostics Market Outlook, by Reagent, Value (US$ Bn), 2018 - 2031
    • 8.1.1. Key Highlights
      • 8.1.1.1. Rapid Testing Kits
      • 8.1.1.2. Assay Based Kits
  • 8.2. Middle East & Africa Shrimp Disease Diagnostics Market Outlook, by Disease, Value (US$ Bn), 2018 - 2031
    • 8.2.1. Key Highlights
      • 8.2.1.1. WSSV (White Spot Syndrome Virus)
      • 8.2.1.2. TSV (Taura Syndrome Virus)
      • 8.2.1.3. YHV/GAV (Yellow Head/Gill Associated Virus)
      • 8.2.1.4. IHHNV (Infectious Hypodermal and Hematopoietic Virus)
      • 8.2.1.5. HPV (Hepatopancreatic Parvovirus)
      • 8.2.1.6. MBV (Monodon Baculovirus)
      • 8.2.1.7. IMNV (Infectious Myonecrosis Virus)
      • 8.2.1.8. NHP-B (Necrotising Hepatopancreatitis Bacteria)
      • 8.2.1.9. MoV (Mourilyan Virus)
      • 8.2.1.10. Early Mortality Syndrome (EMS)
  • 8.3. Middle East & Africa Shrimp Disease Diagnostics Market Outlook, by End User, Value (US$ Bn), 2018 - 2031
    • 8.3.1. Key Highlights
      • 8.3.1.1. Fisheries
      • 8.3.1.2. Aquaculture Laboratories
      • 8.3.1.3. Marine Laboratories
      • 8.3.1.4. Education and Research Institutes
      • 8.3.1.5. Others
  • 8.4. Middle East & Africa Shrimp Disease Diagnostics Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
    • 8.4.1. Key Highlights
      • 8.4.1.1. GCC Shrimp Disease Diagnostics Market by Reagent, Value (US$ Bn), 2018 - 2031
      • 8.4.1.2. GCC Shrimp Disease Diagnostics Market by Disease, Value (US$ Bn), 2018 - 2031
      • 8.4.1.3. GCC Shrimp Disease Diagnostics Market by End User, Value (US$ Bn), 2018 - 2031
      • 8.4.1.4. South Africa Shrimp Disease Diagnostics Market by Reagent, Value (US$ Bn), 2018 - 2031
      • 8.4.1.5. South Africa Shrimp Disease Diagnostics Market by Disease, Value (US$ Bn), 2018 - 2031
      • 8.4.1.6. South Africa Shrimp Disease Diagnostics Market by End User, Value (US$ Bn), 2018 - 2031
      • 8.4.1.7. Egypt Shrimp Disease Diagnostics Market by Reagent, Value (US$ Bn), 2018 - 2031
      • 8.4.1.8. Egypt Shrimp Disease Diagnostics Market by Disease, Value (US$ Bn), 2018 - 2031
      • 8.4.1.9. Egypt Shrimp Disease Diagnostics Market by End User, Value (US$ Bn), 2018 - 2031
      • 8.4.1.10. Nigeria Shrimp Disease Diagnostics Market by Reagent, Value (US$ Bn), 2018 - 2031
      • 8.4.1.11. Nigeria Shrimp Disease Diagnostics Market by Disease, Value (US$ Bn), 2018 - 2031
      • 8.4.1.12. Nigeria Shrimp Disease Diagnostics Market by End User, Value (US$ Bn), 2018 - 2031
      • 8.4.1.13. Rest of Middle East & Africa Shrimp Disease Diagnostics Market by Reagent, Value (US$ Bn), 2018 - 2031
      • 8.4.1.14. Rest of Middle East & Africa Shrimp Disease Diagnostics Market by Disease, Value (US$ Bn), 2018 - 2031
      • 8.4.1.15. Rest of Middle East & Africa Shrimp Disease Diagnostics Market by End User, Value (US$ Bn), 2018 - 2031
    • 8.4.2. BPS Analysis/Market Attractiveness Analysis

9. Competitive Landscape

  • 9.1. Disease vs Reagent Heatmap
  • 9.2. Company Market Share Analysis, 2023
  • 9.3. Competitive Dashboard
  • 9.4. Company Profiles
    • 9.4.1. HiMedia Laboratories
      • 9.4.1.1. Company Overview
      • 9.4.1.2. Product Portfolio
      • 9.4.1.3. Financial Overview
      • 9.4.1.4. Business Strategies and Development
    • 9.4.2. Speedy Assay Sdn Bhd
      • 9.4.2.1. Company Overview
      • 9.4.2.2. Product Portfolio
      • 9.4.2.3. Financial Overview
      • 9.4.2.4. Business Strategies and Development
    • 9.4.3. REAGEN LLC
      • 9.4.3.1. Company Overview
      • 9.4.3.2. Product Portfolio
      • 9.4.3.3. Financial Overview
      • 9.4.3.4. Business Strategies and Development
    • 9.4.4. FUJIKURA KASEI CO., LTD.
      • 9.4.4.1. Company Overview
      • 9.4.4.2. Product Portfolio
      • 9.4.4.3. Financial Overview
      • 9.4.4.4. Business Strategies and Development
    • 9.4.5. GeneReach Biotechnology Corp.
      • 9.4.5.1. Company Overview
      • 9.4.5.2. Product Portfolio
      • 9.4.5.3. Financial Overview
      • 9.4.5.4. Business Strategies and Development
    • 9.4.6. Thermo Fisher Scientific
      • 9.4.6.1. Company Overview
      • 9.4.6.2. Product Portfolio
      • 9.4.6.3. Financial Overview
      • 9.4.6.4. Business Strategies and Development
    • 9.4.7. Lab - Ind Resource Sdn Bhd.
      • 9.4.7.1. Company Overview
      • 9.4.7.2. Product Portfolio
      • 9.4.7.3. Financial Overview
      • 9.4.7.4. Business Strategies and Development
    • 9.4.8. SUREBIO
      • 9.4.8.1. Company Overview
      • 9.4.8.2. Product Portfolio
      • 9.4.8.3. Financial Overview
      • 9.4.8.4. Business Strategies and Development
    • 9.4.9. Auro Biotechnologies Pvt. Ltd.
      • 9.4.9.1. Company Overview
      • 9.4.9.2. Product Portfolio
      • 9.4.9.3. Financial Overview
      • 9.4.9.4. Business Strategies and Development

10. Appendix

  • 10.1. Research Methodology
  • 10.2. Report Assumptions
  • 10.3. Acronyms and Abbreviations